Oruka Therapeutics, Inc. SEC filings ORKA
Oruka Therapeutics, Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Jun 26, 2009. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 26, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 27, 2026 | — |
| EFFECT | Filing | Apr 10, 2026 | — |
| CORRESP | Letter to the SEC | Apr 8, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 7, 2026 | — |
| EFFECT | Filing | Mar 11, 2025 | — |
| EFFECT | Filing | Nov 26, 2024 | — |
| CORRESP | Letter to the SEC | Nov 22, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2024 | — |
| 425 | Current report | Aug 27, 2024 | — |
| 425 | Current report | Aug 16, 2024 | — |
| 425 | Current report | Aug 15, 2024 | — |
| 425 | Form 425 | Aug 9, 2024 | — |
| 425 | Filing | Aug 1, 2024 | — |
| SEC STAFF LETTER | Filing | Jul 26, 2024 | — |
| EFFECT | Filing | Jul 24, 2024 | — |
| CORRESP | Letter to the SEC | Jul 23, 2024 | — |
| CORRESP | Letter to the SEC | Jul 22, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2024 | — |
| SEC STAFF LETTER | Filing | Jul 12, 2024 | — |
| CORRESP | Letter to the SEC | Jul 9, 2024 | — |
| 425 | Current report | Jul 9, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 3, 2024 | — |
| CORRESP | Letter to the SEC | Jun 18, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 11, 2024 | — |
| 425 | Form 425 | Jun 6, 2024 | — |
| 425 | Filing | Apr 25, 2024 | — |
| 425 | Filing | Apr 3, 2024 | — |
| RW | Filing | Apr 2, 2021 | — |
| EFFECT | Filing | Mar 30, 2021 | — |
| CORRESP | Letter to the SEC | Mar 26, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 26, 2021 | — |
| EFFECT | Filing | May 20, 2020 | — |
| CORRESP | Letter to the SEC | May 18, 2020 | — |
| UPLOAD | Letter from the SEC | May 14, 2020 | — |
| CT ORDER | Filing | May 17, 2019 | — |
| CT ORDER | Filing | May 10, 2018 | — |
| CT ORDER | Filing | Dec 13, 2017 | — |
| EFFECT | Filing | May 12, 2017 | — |
| CORRESP | Letter to the SEC | May 10, 2017 | — |
| CORRESP | Letter to the SEC | May 10, 2017 | — |
| CORRESP | Letter to the SEC | May 8, 2017 | — |
| UPLOAD | Letter from the SEC | May 5, 2017 | — |
| CT ORDER | Filing | Apr 14, 2017 | — |
| CT ORDER | Filing | Sep 14, 2016 | — |
| CT ORDER | Filing | Mar 1, 2016 | — |
| EFFECT | Filing | Oct 26, 2015 | — |
| EFFECT | Filing | Jul 20, 2015 | — |
| CORRESP | Letter to the SEC | Jul 16, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 15, 2015 | — |
| D | Filing | Jun 25, 2015 | — |
| CT ORDER | Filing | Jun 15, 2015 | — |
| CT ORDER | Filing | May 20, 2015 | — |
| CT ORDER | Filing | Apr 22, 2015 | — |
| CT ORDER | Filing | Nov 20, 2014 | — |
| CT ORDER | Filing | Sep 17, 2014 | — |
| CT ORDER | Filing | Jun 27, 2014 | — |
| EFFECT | Filing | May 6, 2014 | — |
| CORRESP | Letter to the SEC | May 2, 2014 | — |
| CT ORDER | Filing | Apr 18, 2014 | — |
| UPLOAD | Letter from the SEC | Apr 14, 2014 | — |
| D | Filing | Feb 20, 2014 | — |
| CT ORDER | Filing | Jul 16, 2013 | — |
| D | Filing | Jun 17, 2013 | — |
| EFFECT | Filing | May 29, 2013 | — |
| CORRESP | Letter to the SEC | May 24, 2013 | — |
| CORRESP | Letter to the SEC | May 23, 2013 | — |
| CORRESP | Letter to the SEC | May 16, 2013 | — |
| CORRESP | Letter to the SEC | Apr 4, 2013 | — |
| UPLOAD | Letter from the SEC | Apr 2, 2013 | — |
| EFFECT | Filing | Feb 14, 2013 | — |
| D | Filing | Feb 1, 2013 | — |
| D | Filing | Dec 28, 2012 | — |
| D | Filing | Oct 31, 2012 | — |
| EFFECT | Filing | Jan 26, 2012 | — |
| CORRESP | Letter to the SEC | Jan 24, 2012 | — |
| CORRESP | Letter to the SEC | Jan 24, 2012 | — |
| UPLOAD | Letter from the SEC | Jan 19, 2012 | — |
| CT ORDER | Filing | Jan 10, 2012 | — |
| D | Filing | Jan 5, 2012 | — |
| CT ORDER | Filing | Jun 15, 2011 | — |
| EFFECT | Filing | Apr 4, 2011 | — |
| CORRESP | Letter to the SEC | Mar 31, 2011 | — |
| UPLOAD | Letter from the SEC | Mar 11, 2011 | — |
| UPLOAD | Letter from the SEC | Dec 22, 2010 | — |
| CORRESP | Letter to the SEC | Dec 21, 2010 | — |
| UPLOAD | Letter from the SEC | Dec 10, 2010 | — |
| CT ORDER | Filing | Sep 7, 2010 | — |
| CT ORDER | Filing | May 11, 2010 | — |
| CT ORDER | Filing | Nov 30, 2009 | — |
| CT ORDER | Filing | Nov 24, 2009 | — |
| D | Filing | Oct 26, 2009 | — |
| CT ORDER | Filing | Aug 27, 2009 | — |
| CT ORDER | Filing | Aug 25, 2009 | — |
| CT ORDER | Filing | Aug 25, 2009 | — |
Showing 94 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ORKA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Menlo Park, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 907654
- Former names
- ARCA biopharma, Inc. (until Aug 30, 2024); NUVELO INC (until Jan 27, 2009); HYSEQ INC (until Jan 28, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.